- Home
- BIIB vs HUBB Comparison
BIIB vs HUBB Comparison
Compare BIIB & HUBB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- HUBB
- Stock Information
- Founded
- BIIB 1978
- HUBB 1888
- Country
- BIIB United States
- HUBB United States
- Employees
- BIIB N/A
- HUBB N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- HUBB Industrial Machinery/Components
- Sector
- BIIB Health Care
- HUBB Technology
- Exchange
- BIIB Nasdaq
- HUBB Nasdaq
- Market Cap
- BIIB 18.8B
- HUBB 20.9B
- IPO Year
- BIIB 1991
- HUBB N/A
- Fundamental
- Price
- BIIB $125.00
- HUBB $407.71
- Analyst Decision
- BIIB Buy
- HUBB Hold
- Analyst Count
- BIIB 27
- HUBB 8
- Target Price
- BIIB $188.17
- HUBB $459.25
- AVG Volume (30 Days)
- BIIB 1.3M
- HUBB 498.7K
- Earning Date
- BIIB 07-31-2025
- HUBB 07-29-2025
- Dividend Yield
- BIIB N/A
- HUBB 1.29%
- EPS Growth
- BIIB 26.39
- HUBB 10.31
- EPS
- BIIB 10.12
- HUBB 14.79
- Revenue
- BIIB $9,816,400,000.00
- HUBB $5,594,600,000.00
- Revenue This Year
- BIIB N/A
- HUBB $7.60
- Revenue Next Year
- BIIB N/A
- HUBB $5.93
- P/E Ratio
- BIIB $12.41
- HUBB $27.57
- Revenue Growth
- BIIB 1.59
- HUBB 1.97
- 52 Week Low
- BIIB $110.04
- HUBB $299.43
- 52 Week High
- BIIB $238.00
- HUBB $481.35
- Technical
- Relative Strength Index (RSI)
- BIIB 45.14
- HUBB 64.97
- Support Level
- BIIB $123.21
- HUBB $385.91
- Resistance Level
- BIIB $129.27
- HUBB $404.66
- Average True Range (ATR)
- BIIB 3.00
- HUBB 7.26
- MACD
- BIIB -0.77
- HUBB 0.76
- Stochastic Oscillator
- BIIB 21.06
- HUBB 89.42
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About HUBB Hubbell Inc
Founded in 1888 by Harvey Hubbell, the eponymous company was the conduit through which the pull-chain lamp socket was originally sold. Hubbell has since grown into an electricity transmission and distribution behemoth, housing more than 75 brands that sell components found on power lines, electrical substations, and within commercial and industrial buildings. The company's primary operations are within the United States, where around 90% of revenue is derived.